4D Molecular Therapeutics Accelerates Phase 3 Trial for 4D-150 in Wet AMD with Early Initiation of 4FRONT-2
4D Molecular Therapeutics Inc. has accelerated its Phase 3 clinical program for 4D-150, a treatment for Wet AMD, with topline data expected in early 2027. The initiation of the 4FRONT-2 trial has also been expedited. This follows positive results from the SPECTRA trial in Diabetic Macular Edema, showing good tolerability and durability. To enhance efficiency, the company has reduced its workforce by 25%.
4D Molecular Therapeutics Inc., a biotechnology company, has announced progress in their Phase 3 clinical program for 4D-150, a therapeutic candidate for Wet Age-related Macular Degeneration (Wet AMD). The company has accelerated the timeline for its 4FRONT-1 Phase 3 trial, with topline data now expected in the first half of 2027. Additionally, the initiation of the 4FRONT-2 trial has been moved ahead of schedule. This advancement follows positive 60-week results from the SPECTRA clinical trial in Diabetic Macular Edema (DME), which demonstrated favorable tolerability and sustained durability. The company has streamlined its organization to focus on late-stage execution, including a 25% workforce reduction, to enhance cost efficiency and support the accelerated clinical programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9509355-en) on August 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
